Symrise Shares Struggle to Find Support Amid Cautious Outlook

Symrise shares fall ~35% from peak, pressured by restrained 2026 growth forecast, new division, and buybacks fail to halt decline. Key Q1 2026 report due April 29.

The equity of Symrise continues to search for a stable footing without success. Having touched a fresh four-week low on Friday and triggered a technical sell signal based on stochastic indicators, the stock now trades just below the €69 level. This represents a decline of approximately 35% from its June peak of €106.55.

Management's Restrained Forecast Weighs on Sentiment

The primary driver behind the persistent downward pressure is the company's cautious forward guidance for 2026. Despite reporting organic sales growth of 2.8% for the past year, Symrise's management has projected organic growth of only 2.0% to 4.0% for the current fiscal year. Market experts suggest the first quarter of 2026 could even see a slight negative organic growth figure, as performance will be measured against a particularly strong prior-year period. Additional headwinds include geopolitical uncertainties and potential tariff risks affecting the company's US operations.

Countermeasures Yet to Alter the Trajectory

Symrise has initiated two key strategies to address the situation, though their impact on the share price has been limited so far. In mid-March, the company established a new "Care & Wellness" division, designed to consolidate cosmetic ingredients and health-promoting active substances under a single umbrella. Furthermore, during just the second week of March, Symrise repurchased 141,747 of its own shares as part of an ongoing buyback program. This program, which extends until October 2026, is authorized for up to €400 million. These actions have, however, failed to reverse the prevailing negative trend.

From a technical perspective, the Relative Strength Index (RSI) stands at 34.6, nearing oversold territory. This condition alone does not constitute a definitive buy signal. Investors are now looking ahead to the interim statement for Q1 2026, scheduled for release on April 29. Should the company's efficiency programs fail to demonstrate visible progress by that time, the downward pressure on the stock is likely to persist.